Glucose lowering to control macrovascular disease in type 2 diabetes: treating the wrong surrogate end point?
Goodarzi
Mark O
MO
Division of Endocrinology, Diabetes and Metabolism, Medical Genetics Institute, Cedars-Sinai Medical Center, and Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Psaty
Bruce M
BM
D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000628:therapy*; D003925:Diabetic Angiopathies / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance
D007004:Hypoglycemic Agents